AlloNK® + Obinutuzumab
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Phase 1/2Active
Key Facts
Indication
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Phase
Phase 1/2
Status
Active
Company
About Artiva Biotherapeutics
Artiva Biotherapeutics is pioneering accessible NK cell therapies with a mission to treat devastating autoimmune diseases and cancers. Leveraging a proprietary manufacturing platform and a strategic partnership with GC Cell Corporation, Artiva's lead program, AlloNK®, is in multiple Phase 1/2 trials for conditions like rheumatoid arthritis and Sjögren's disease. The company differentiates itself through a scalable, allogeneic approach designed to enable outpatient treatment and broad patient access.
View full company profile